Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2010, Article ID 489759, 11 pages
Research Article

Regression of Human Prostate Tumors and Metastases in Nude Mice following Treatment with the Recombinant Oncolytic Vaccinia Virus GLV-1h68

1Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA
2Department of Biochemistry, University of Wuerzburg, D-97074 Wuerzburg, Germany
3Institute for Medical Radiation and Cell Research, University of Wuerzburg, D-97078 Wuerzburg, Germany
4Rudolf Virchow Center for Experimental Biomedicine, University of Wuerzburg, D-97078 Wuerzburg, Germany
5Institute for Molecular Infection Biology, University of Wuerzburg, D-97078 Wuerzburg, Germany
6Department of Radiation Oncology, Moores Cancer Center, University of California, San Diego, 3855 Health Sciences Drive 0843, La Jolla, CA 92093-0843, USA

Received 17 July 2009; Revised 14 October 2009; Accepted 13 January 2010

Academic Editor: Colin Cooper

Copyright © 2010 Ivaylo Gentschev et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Virotherapy using oncolytic vaccinia virus strains is one of the most promising new strategies for cancer therapy. In the current study, we analyzed the therapeutic efficacy of the oncolytic vaccinia virus GLV-1h68 against two human prostate cancer cell lines DU-145 and PC-3 in cell culture and in tumor xenograft models. By viral proliferation assays and cell survival tests, we demonstrated that GLV-1h68 was able to infect, replicate in, and lyse these prostate cancer cells in culture. In DU-145 and PC-3 tumor xenograft models, a single intravenous injection with GLV-1h68 resulted in a significant reduction of primary tumor size. In addition, the GLV-1h68-infection led to strong inflammatory and oncolytic effects resulting in drastic reduction of regional lymph nodes with PC-3 metastases. Our data documented that the GLV-1h68 virus has a great potential for treatment of human prostate carcinoma.